Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Sell
25
ADAP Quote, Financials, Valuation and Earnings
Last price:
$0.28
Seasonality move
:
-12.65%
Day range:
$0.27 - $0.28
52-week range:
$0.20 - $1.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.39x
P/B ratio:
6.03x
Volume:
245.7K
Avg. volume:
602.6K
1-year change:
-78.74%
Market cap:
$71.6M
Revenue:
$178M
EPS (TTM):
-$0.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
$11.1M | -$0.14 | -91.39% | -8.33% | $1.45 |
|
AUTL
Autolus Therapeutics PLC
|
$12.9M | -$0.23 | -80.39% | -10.73% | $9.86 |
|
BCYC
Bicycle Therapeutics PLC
|
$9.4M | -$0.93 | 0.73% | -20.58% | $26.27 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$0.01 | -100% | -87.66% | $7.32 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.27 | $1.45 | $71.6M | -- | $0.00 | 0% | 0.39x |
|
AUTL
Autolus Therapeutics PLC
|
$2.44 | $9.86 | $649.4M | -- | $0.00 | 0% | -- |
|
BCYC
Bicycle Therapeutics PLC
|
$7.78 | $26.27 | $538.8M | -- | $0.00 | 0% | 19.61x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$0.84 | $17.94 | $4.2M | -- | $0.00 | 0% | 0.87x |
|
MREO
Mereo BioPharma Group PLC
|
$1.75 | $7.32 | $278.3M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.05 | $104.00 | $304.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
-211.44% | 3.289 | 50.03% | 1.57x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.256 | -- | 8.74x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.061 | -- | 14.57x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.010 | -- | 1.20x |
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.029 | -- | -- |
|
NCNA
NuCana PLC
|
-- | -1.015 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.4M | -$44.1M | -107.36% | -199.63% | -619.47% | -$67.8M |
|
AUTL
Autolus Therapeutics PLC
|
-$9M | -$65.2M | -49.92% | -49.92% | -643.43% | -$83.8M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$70M | -27.79% | -28.27% | -619.32% | -$87M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$11M | -- | -- | -- | -$8.6M |
|
NCNA
NuCana PLC
|
-- | -$3.5M | -- | -- | -- | -$4M |
Adaptimmune Therapeutics PLC vs. Competitors
-
Which has Higher Returns ADAP or AUTL?
Autolus Therapeutics PLC has a net margin of -653.18% compared to Adaptimmune Therapeutics PLC's net margin of -781.13%. Adaptimmune Therapeutics PLC's return on equity of -199.63% beat Autolus Therapeutics PLC's return on equity of -49.92%.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M -
What do Analysts Say About ADAP or AUTL?
Adaptimmune Therapeutics PLC has a consensus price target of $1.45, signalling upside risk potential of 437.5%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.86 which suggests that it could grow by 303.92%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC2 4 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is ADAP or AUTL More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.179, which suggesting that the stock is 117.923% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.813, suggesting its more volatile than the S&P 500 by 81.299%.
-
Which is a Better Dividend Stock ADAP or AUTL?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or AUTL?
Adaptimmune Therapeutics PLC quarterly revenues are $7.3M, which are smaller than Autolus Therapeutics PLC quarterly revenues of $9M. Adaptimmune Therapeutics PLC's net income of -$47.6M is higher than Autolus Therapeutics PLC's net income of -$70.2M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.39x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.39x -- $7.3M -$47.6M AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M
-
Which has Higher Returns ADAP or BCYC?
Bicycle Therapeutics PLC has a net margin of -653.18% compared to Adaptimmune Therapeutics PLC's net margin of -608.94%. Adaptimmune Therapeutics PLC's return on equity of -199.63% beat Bicycle Therapeutics PLC's return on equity of -28.27%.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M -
What do Analysts Say About ADAP or BCYC?
Adaptimmune Therapeutics PLC has a consensus price target of $1.45, signalling upside risk potential of 437.5%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $26.27 which suggests that it could grow by 237.7%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC2 4 0 BCYCBicycle Therapeutics PLC5 3 0 -
Is ADAP or BCYC More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.179, which suggesting that the stock is 117.923% more volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.408, suggesting its more volatile than the S&P 500 by 40.784%.
-
Which is a Better Dividend Stock ADAP or BCYC?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or BCYC?
Adaptimmune Therapeutics PLC quarterly revenues are $7.3M, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $10M. Adaptimmune Therapeutics PLC's net income of -$47.6M is higher than Bicycle Therapeutics PLC's net income of -$60.8M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.39x versus 19.61x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.39x -- $7.3M -$47.6M BCYCBicycle Therapeutics PLC19.61x -- $10M -$60.8M
-
Which has Higher Returns ADAP or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -653.18% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -199.63% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About ADAP or BDRX?
Adaptimmune Therapeutics PLC has a consensus price target of $1.45, signalling upside risk potential of 437.5%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 2041.28%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC2 4 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is ADAP or BDRX More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.179, which suggesting that the stock is 117.923% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.
-
Which is a Better Dividend Stock ADAP or BDRX?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or BDRX?
Adaptimmune Therapeutics PLC quarterly revenues are $7.3M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$47.6M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.39x versus 0.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.39x -- $7.3M -$47.6M BDRXBiodexa Pharmaceuticals PLC0.87x -- -- --
-
Which has Higher Returns ADAP or MREO?
Mereo BioPharma Group PLC has a net margin of -653.18% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -199.63% beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M MREOMereo BioPharma Group PLC-- -$0.10 -- -
What do Analysts Say About ADAP or MREO?
Adaptimmune Therapeutics PLC has a consensus price target of $1.45, signalling upside risk potential of 437.5%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.32 which suggests that it could grow by 318.54%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC2 4 0 MREOMereo BioPharma Group PLC6 0 0 -
Is ADAP or MREO More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.179, which suggesting that the stock is 117.923% more volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.683%.
-
Which is a Better Dividend Stock ADAP or MREO?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or MREO?
Adaptimmune Therapeutics PLC quarterly revenues are $7.3M, which are larger than Mereo BioPharma Group PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$47.6M is lower than Mereo BioPharma Group PLC's net income of -$12.9M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.39x versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.39x -- $7.3M -$47.6M MREOMereo BioPharma Group PLC-- -- -- -$12.9M
-
Which has Higher Returns ADAP or NCNA?
NuCana PLC has a net margin of -653.18% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -199.63% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M NCNANuCana PLC-- -$0.63 -- -
What do Analysts Say About ADAP or NCNA?
Adaptimmune Therapeutics PLC has a consensus price target of $1.45, signalling upside risk potential of 437.5%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 207071.32%. Given that NuCana PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe NuCana PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings ADAPAdaptimmune Therapeutics PLC2 4 0 NCNANuCana PLC0 1 0 -
Is ADAP or NCNA More Risky?
Adaptimmune Therapeutics PLC has a beta of 2.179, which suggesting that the stock is 117.923% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.561%.
-
Which is a Better Dividend Stock ADAP or NCNA?
Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADAP or NCNA?
Adaptimmune Therapeutics PLC quarterly revenues are $7.3M, which are larger than NuCana PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$47.6M is lower than NuCana PLC's net income of -$3.1M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.39x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADAPAdaptimmune Therapeutics PLC0.39x -- $7.3M -$47.6M NCNANuCana PLC-- -- -- -$3.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 4.15% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is up 1.39% over the past day.
Sell
42
VLCN alert for Jul 17
Volcon [VLCN] is up 183.82% over the past day.
